Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Dec 30, 2021 10:56am
90 Views
Post# 34270776

RE:Trading December 29

RE:Trading December 29CSE/OTC is Silly Season 24/7/365. Investors are screwed without the Nasdaq uplist. Too much at stake in 2022 since the punishing consolidation of shares @ 1 for 100 reverse split. If the company gets deeper into 2022 and does another PP like all the prior PP's we can kiss our remaining @ss-ets goodbye. We have now been leveraged to the brink of disaster for all those holding pre-split shares. We cannot trust management will have our best interest in hand when the likes of Kulwant Malhi cones around yet again to flip millions of fire sale shares. We need the stock to be trading north of $30U$D and it's only ever going in the opposite direction. Every share represents a 100 shares of your hard earned money. It represents 200 shares for all shares held from the 1st reverse split on Christopher J. Moreau's watch. The time for uplist is ASAP. We can't wait and wait and wait indefinitely for that to happen, or wait and wait and wait for CJM to make good on his promise to all shareholders that we should trust him - "The best is yet to come.". WHEN?
<< Previous
Bullboard Posts
Next >>